Four gold(I) carbene complexes featuring 4-ferrocenyl substituted imidazol-2-ylidene ligands were investigated for antiproliferative and antivascular properties. They were active against a panel of seven cancer cell lines, including multidrugresistant ones, with low micromolar or nanomolar IC50 (72 h) values, according to their lipophilicity and cellular uptake. The delocalised lipophilic cationic complexes 8 and 10 acted by increasing the reactive oxygen species in two ways: via a genuine ferrocene effect and by inhibiting the thioredoxin reductase. Both complexes gave rise to a reorganization of the F-actin cytoskeleton in endothelial and melanoma cells, associated with a G1 phase cell cycle arrest and a retarded cell migration. They proved antiangiogenic in tube formation assays with endothelial cells and vascular-disruptive on real blood vessels in the chorioallantoic membrane of chicken eggs. Biscarbene complex 10 was also tolerated well by mice where it led to a volume reduction of xenograft tumors by up to 80%.
Introduction
A common strategy to improve the impact of metallodrugs is the optimization of their pharmacokinetic and pharmacodynamic properties. [1, 2] A less frequent approach uses the decoration of bioactive metal fragments with ligands or shuttle groups that show some bioactivity or functionality of their own. In felicitous cases pleiotropic drugs result that not only retain the individual properties of metal and ligand but also exhibit some new effects. [3] [4] [5] [6] N-heterocyclic carbene (NHC) ligands are poor leaving groups and thus lend themselves ideally to the permanent introduction of modulatory substituents at their heterocycle. [3, 6] Previously, we reported on gold(I) mono-and biscarbene complexes (1, 2) with imidazole ligands that had been modeled on the natural antivascular agent combretastatin A-4 (CA-4) (Figure1). [7] [8] [9] They proved highly cytotoxic and efficacious against cancer cell lines of various entities with IC50 values in the low micromolar or even submicromolar range. Despite their different molecular mechanism of action when compared to CA-4, they also retained a significant antivascular activity both in vitro and in vivo. Since gold NHC complexes had been reported to interfere with the redox machinery of cells, e.g., the mitochondria or specific antioxidative enzymes such as thioredoxin reductase (TrxR), [3, 5, 6] we intended to attach an electronically coupled, redox-active ferrocenyl residue to the NHC ligand of gold(I) complexes. The concept of enhancing the activity or selectivity of anticancer metallodrugs by introduction of further metal centers is not new. [10] [11] [12] [13] Ferrocene is known to activate lymphocytes and to exert distinct antitumor effects which are associated with the production and regulation of reactive oxygen species (ROS) and the oxidation of Ras proteins at cysteine sites. [14] A host of antitumoral ferrocene derivatives have been published, including conjugates with peptides, benzotriazoles, nucleobases, estrogen receptor modulators, and fungal cytotoxins like illudin M. [15] [16] [17] [18] [19] There are also reports on gold complexes conjugated to ferrocene with distinct anticancer activities against various cancer cell lines. [11, 20] In the present paper, we report on the synthesis and structure-dependent anticancer properties in vitro and in vivo of new carbene complexes of gold(I) featuring ferrocenyl-coupled imidazol-2-ylidene ligands.
Results and Discussion

Chemistry
The N-alkyl-5-ferrocenyl-4-phenyl-imidazoles 4 were obtained via a Van-Leusen imidazole synthesis starting from ferrocenyl carboxaldehyde and the TosMIC reagent 3 (Scheme 1). Alkylation of complexes 4 with iodomethane or iodoethane afforded the corresponding imidazolium salts 5, which were treated with silver(I) oxide to give the silver(I) carbene complexes 6. Their transmetallation with chlorido(dimethylsulfide)gold(I) gave the chlorido(NHC)gold(I) complexes 7. The cationic phosphano gold complex 8 was obtained from the reaction of 7b with PPh3 and NaBF4. [21] Scheme 1. Syntheses of gold(I) NHC complexes 7, 8, and 10. Reagents and conditions: a) ferrocenyl carboxaldehyde, 33% MeNH2/EtOH or 2M EtNH2/THF, AcOH, EtOH, reflux, 2 h, then 3, K2CO3, EtOH, reflux, 3 h; b) MeI or EtI, MeCN, 80 °C, 16 h; c) Ag2O, CH2Cl2, r.t., 16 h; d) Cl(Me2S)Au, CH2Cl2, r.t., 16 h; e) 7b, NaBF4, PPh3, acetone, r.t., 1 h; f) NaBF4, acetone, r.t., 16 h, 100%; g) Ag2O, CH2Cl2, r.t., 5 h, then Cl(Me2S)Au (0.5 equiv.), CH2Cl2, r.t., 16 h.
The cationic biscarbene complex 10 was prepared from imidazolium iodide 5b which had its counter anion substituted for BF4 to give complex 9. This was converted with Ag2O to the corresponding silver carbene complex which was not isolated but transmetallated with 0.5 equivalents of Cl(Me2S)Au to afford complex 10 (Scheme 1, bottom row). Crystals of complex 10 suitable for X-ray diffraction analyses were grown by slow infusion of ether into a saturated CH2Cl2 solution at 4 °C ( Figure  2 ). The cyclic voltammograms of the new complexes showed an anodic shift of the redox potential E1/2 relative to ferrocene, e.g. by 145 mV in the case of neutral 7b (cf. Supporting Information). (1), N1-C4 1.38(1), C4-C5 1.44(1), C5-Fe 2.092(8), C1-Au-C1 180.0, Au-C1-N1 127.0, N1-C1-N2 105.8 (7) , C5-C4-N1 126.8 (8) .
Antiproliferative activity in vitro
The effect of complexes 7, 8, and 10 on the growth of cancer cells was evaluated in proliferation assays using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) that is reduced to a violet formazan in viable cells. [22] To assess potential selectivities for cancer over non-malignant cells, CCD18-Co colorectal myofibroblasts were included ( Table 1 ). The N-methylated monocarbene complex 7a was antiproliferative with IC50 values mostly in the lower micromolar range (IC50 (72 h) = ca. 7-20 !M), while its N-ethyl analog 7b was significantly more active (IC50 (72 h) = ca. 0.2-4 !M). Moreover, we found that replacing the chlorido ligand by a triphenylphosphane or a second NHC ligand, as in the cationic complexes 8 and 10, further enhanced the antiproliferative effect, giving rise to IC50 values in the lower submicromolar range with complex 10 being slightly more active than complex 8. This trend of increasing cytotoxicities when substituting a chlorido for a phosphane or NHC ligand has previously been observed for NHC gold(I) complexes of the benzimidazol-2-ylidene type by Rubbiani et al. [23] Interestingly, all complexes 7, 8, and 10 were active also against multidrug-resistant tumor cell lines such as HT-29 colon, [24, 25] MCF-7/Topo breast, 26, 27 and -with the exception of complex 7a -KB-V1/Vbl cervix carcinomas. Pretreatment of KB-V1/Vbl cells which overexpress P-glycoprotein "/ F% 1 [28] [29] [30] with verapamil, an inhibitor of this efflux transporter, for 24 h improved the effect of all complexes by a factor of 4 to 35. This suggests that they are themselves substrates of P-gp, like the CA-4 derived biscarbene complexes 2. [9] The complexes 7, 8, and 10 also strongly inhibited the growth of human umbilical vein endothelial cells (HUVEC), which is a hint at a potential antivascular activity. In contrast, the non-malignant CCD18-Co fibroblasts were affected only at higher complex concentrations. 
Cellular accumulation and lipophilicity
The activity of drugs depends on their intracellular accumulation. The uptake of complexes 7, 8, and 10 by HCT-116 cells that had been exposed to 0.5 !M concentrations of the compounds for 24 h, was measured by ICP-MS analysis of their iron content (Table  2) . Additionally, the coefficient log P for their partition between 1octanol and water was determined in order to identify correlations between lipophilicity, cellular uptake and cytotoxicity. [31, 32] They displayed a largely hydrophilic character with negative log P values that correlate with their respective cellular accumulation. The most hydrophilic complex 7a showed the least uptake. Its more lipophilic N-ethyl analog 7b was taken up to a greater extent. The cytotoxicities of the complexes 7 tie in nicely with their lipophilicities and accumulations. Complex 7b is active in HCT-116 cells with an IC50 value about 50 times lower than that of complex 7a. The cationic phosphane complex 10 has a log P value near 0 and thus a greater lipophilicity than the neutral complexes 7. Consequently, it also showed the greatest accumulation in HCT-116 cells which fits in with its high cytotoxicity against this cancer cell line. 
Effects on the cytoskeletal organization
Like the CA-4 derived complexes 1 and 2, [7] [8] [9] the new ferrocenyl complexes did not interfere with the polymerization of tubulin or with the organization of microtubules in cells, but induced a distinct reorganization of the actin cytoskeleton in both 518A2 melanoma cells and non-malignant HUVEC. For instance, when we visualized microtubules (not shown) and filamentous actin (F-actin) in these cells after treatment with 500 nM of 8 or 250 nM of 10, we saw changes only in the organization of the latter (Figure 3 ). Both complexes led to the formation of sheaves of parallel actin fibers running across the entire cell bodies, in contrast to the cortical networks of actin observed in untreated control cells. The stress fiber formation was more pronounced in HUVEC than in the tumor cells, and more for complex 10 than for complex 8. 
Effects on tumor cell cycle and migration
The effects of complexes 8 and 10 on the cell cycle progression of 518A2 melanoma cells were analyzed by propidium iodide staining and flow cytometry ( Figure 4A ). Both complexes induced a significant accumulation of cells in the G1 phase, with complex 10 again being slightly more effective. The fractions of cells in S and G2/M phase were distinctly reduced while the sub-G1 population of apoptotic cells rose slightly for the applied concentrations of complexes 8 (500 nM) and 10 (250 nM). Both, the reduced dynamics of the actin cytoskeleton and the marked G1 phase arrest diminished the motility and thus invasiveness of the melanoma cells. [33, 34] In so-called wound healing assays the complexes 8 and 10 reduced their ability to close artificial wounds, i.e., scratches in cell monolayers when compared to untreated cells. While treatment of 518A2 cells with 500 nM of complex 8 for 48 h reduced the wound healing to ca. 70%, the biscarbene complex 10 was a more potent inhibitor of cell migration, reducing the wound healing to ca. 40% when applied at the same concentration ( Figure 4B ). 
Interference with the tumor cell redox poise
The thioredoxin reductase (TrxR) is involved in maintaining the intracellular redox homeostasis and plays an important role in the regulation of cell proliferation and survival. [36, 37] Its inhibition leads to an increase of reactive oxygen species (ROS) in cells, to an interference with mitochondrial functions, and eventually to apoptosis. Since TrxR had already been identified as an important target of gold(I) NHC complexes [3, 5, 6, 38, 39] we analyzed the cationic complexes 8 and 10 for a potential inhibition of isolated TrxR in vitro. The phosphane complex 8 proved a potent TrxR inhibitor with an EC50 = 0.6 ± 0.1 !M, while the biscarbene complex 10 was slightly less effective with an EC50 = 1.5 ± 0.2 !M. A possible explanation for this difference is that triphenylphosphane is a better leaving group than an NHC ligand. This allows a faster binding interaction of the gold center of complex 8 with the selenocysteine residue in the active site of the TrxR. Recently, Rubbiani et al. reported a similar gradation of the TrxR inhibiting effects of phosphane vs. NHC substituted benzimidazolylidene gold(I) complexes. [23, 38] The different potential of complexes 7b, 8, and 10 to inhibit the selenoenzyme TrxR was also assessed by a model reaction with in situ generated seleno-L-cysteine and MS analytics of the resulting adducts as previously described. [40, 41] We found that complexes 7b and 8 readily formed mono selenol adducts with substitution of the chloro or phosphane ligands, respectively, while the biscarbene complex 10 did not (cf. Supporting Information). Additionally, we tested them for inhibition of purified poly(ADPribose) polymerase 1 (PARP-1), an enzyme that plays an important role during the initiation of DNA repair and in drug resistance mechanisms of cancer cells. PARP-1 has also been identified, recently, as a target for gold complexes as well as for heteronuclear iron-gold complexes. [11, 42, 43] Complex 10 was a more effective inhibitor of PARP-
reported a trinuclear Fe-Au(III) complex that also inhibited PARP-1 with an EC50 of ca. 1 !M. [11] It should be noted, though, that other Au(I) and Au(III) complexes with N-donor and phosphane ligands are known that inhibit PARP-1 with EC50 values in the nanomolar range. [42, 43] Reactive oxygen species (ROS) are associated with the mode of action of ferrocene derivatives. There are numerous studies of the correlation between ROS production and antiproliferative effects of ferrocenes, including heteronuclear ferrocene-gold complexes. [14, 20, 44] The effect of complexes 8 and 10 on the ROS levels in 518A2 melanoma cells was now investigated by the nitroblue tetrazolium chloride (NBT) test ( Figure 5A ). When applied at lower concentrations, only complex 10 led to an increase of ROS. At a concentration of 500 nM it caused a 1.6 times higher level of ROS when compared with untreated control cells, while complex 8 had virtually no effect at this concentration. However, at the highest applied concentration of 1 !M both complexes raised the ROS levels equally to ca. 180 % relative to controls. There seem to be at least two ROS increasing effects: a genuine ferrocene effect, which explains the higher ROS levels initiated by the bisferrocenyl complex 10 at lower concentrations, and the rise of ROS levels brought about via TrxR inhibition 38, 45, 46 which is more pronounced for the monoferrocenyl complex 8 and which overrides the stronger ferrocene effect by complex 10 at higher concentrations. The mitochondrial membrane potential "#m is known to be affected by the inhibition of TrxR by gold(I) complexes. [45] [46] [47] [48] Both complexes 8 and 10 are delocalized lipophilic cations (DLC), which are known to accumulate in mitochondria, disturb essential functions of these, and lead to the loss of "#m, eventually inducing the intrinsic pathway of apoptosis. [49] [50] [51] The effects of complexes 8 and 10 on the "#m in 518A2 melanoma cells were evaluated by a JC-1 assay ( Figure 5B ). Both complexes initiated a concentration-dependent reduction in the fraction of cells with an intact "#m. Despite its less pronounced TrxR inhibition the biscarbene complex 10, when applied at 1 !M, reduced the fraction of cells with unaltered "#m to ca. 45%, and thus more strongly than complex 8 which left ca. 65% of mitochondria with intact "#m. A possible explanation lies in the higher lipophilicity of complex 10 which facilitates its uptake into mitochondria. [52] Antivascular effects Tube formation assay: To assess the antiangiogenic activity of complexes 8 and 10 we performed in vitro tube formation assays which are based on the ability of vascular endothelial cells to form interconnected networks of capillary-like structures when grown on an extracellular membrane matrix support such as matrigel. [53] For this, HUVEC were seeded on matrigel, treated with various concentrations of the test compounds and the effects on the formation of tubular networks were documented after 24 h of incubation. Figure 6 shows the results. While control cells had built up highly organized networks of capillarylike structures, both complexes 8 and 10 strongly impaired the formation of such tubular structures when applied at concentrations as low as 100 nM. The chorioallantoic membrane (CAM) of fertilized chicken eggs is highly vascularized and serves as the respiratory system. [54, 55] It can be used as a simple in vivo model system to study the antiangiogenic or vascular-disruptive effects of new drug candidates. [9, [54] [55] [56] Figure 7 depicts the antivascular effects of complexes 8 and 10 in comparison to the normal development of blood vessels in the CAM. After 6 h of incubation complex 8 had destroyed nearly all smaller capillaries while complex 10 had affected even bigger vessels and had induced hemorrhages. These effects were quantified by a vessel area analysis based on a fractal analysis as described previously. [9, 57] The area of blood vessels was decreased to 47 ± 6% by complex 8, and to 27 ± 1% by complex 10. After 24 h of incubation with complex 8 the vasculature within the treated area had recovered and the sprouting of new blood vessels was detected. In contrast, treatment with complex 10 for 24 h led to a further destruction of the vasculature. 
In vivo mouse xenograft model
The antitumoral activity of biscarbene complex 10 was further assessed in vivo using a Balb/c mouse xenograft model of invasive B16-F10 melanoma. The results are shown in Figure 8 . Complex 10 was administered intraperitoneally to the mice twice on two consecutive days (each time 7.5 mg/kg body weight on days 1, 2, 7, and 8). This induced a considerable reduction in tumor volumes to 18-48% of the initial size after twelve days while the volumes of untreated B16-F10 tumors increased by 1.6-to 1.9-fold. The weight of the mice remained nearly the same as at the beginning of the experiment. Thus, it can be concluded from this preliminary study that complex 10 exhibits a significant in vivo antitumor activity against this type of highly metastatic melanoma while being tolerated very well by the mice. 
Conclusions
The ferrocenyl substituted NHC gold(I) complexes 7a, 7b, 8, and 10 showed activity against various tumor cell entities with IC50 values in the lower micromolar or even submicromolar range. In xenografted mice complex 10 led to significant reductions of the tumor volumes while being tolerated well by the animals. The cytotoxicity of the complexes is correlated with their cellular uptake, which is dependent on their lipophilicity. The mechanism of action of complexes 8 and 10 was studied in detail. They induced a distinct reorganization of the F-actin cytoskeleton in human vascular endothelial and melanoma cells, which was associated with an accumulation of the cells in the G1 phase of the cell cycle leading to a significant antimigratory effect. Moreover, complexes 8 and 10 are potent inhibitors of the redox enzyme TrxR with complex 8 being about 2.5 times more effective than complex 10. This is in line with findings by Rubbiani et al. for similar gold(I) NHC complexes and is most likely due to the lower stability of complex 8 leading to a higher reactivity toward nucleophiles present in the active site of the TrxR enzyme. [23, 38] Our results indicate that not only the inhibition of TrxR but also the presence of the ROS regulating/producing ferrocene moieties in complexes 8 and 10 are responsible for the observed increase in the cellular ROS levels. The accumulation of ROS in the investigated melanoma cells was also associated with a decrease in the mitochondrial membrane potential. Such antimitochondrial effects are typical of agents that alter the intracellular redox homeostasis. [45] [46] [47] [48] The complexes 8 and 10 also showed distinct antivascular effects, such as an inhibition of the formation of vessel-like structures by HUVEC in vitro, and a disruption of the vasculature in the CAM of fertilized chicken eggs. This pleiotropic spectrum of anticancer effects in vitro and in vivo makes these new heteronuclear NHC complexes promising drug candidates. We will now study their effects on cancer-relevant signal transduction pathways by proteomic techniques known to be applicable to gold complexes such as ELISA microarray analyses [58, 59] or two-dimensional difference gel electrophoresis. [60] Experimental Section General: Melting points are uncorrected; IR spectra were recorded on an FT-IR spectrophotometer with ATR sampling unit; NMR spectra were run on 300 and 500 MHz spectrometers; chemical shifts are given in ppm ($) downfield from tetramethylsilane as internal standard for 1 
1,3-Diethyl-5-ferrocenyl-4-phenylimidazolium iodide (5b):
Compound 4b (100 mg, 0.28 mmol) was dissolved in acetonitrile (25 mL) and iodoethane (1.5 mL) was added. The reaction mixture was stirred at 85 °C for 24 h. The solvent was evaporated and the residue was dried in vacuum. Yield: 130 mg (0.25 mmol, 89%); yellow gum; 1 
Iodido-(1,3-dimethyl-4-ferrocenyl-5-phenylimidazol-2-ylidene)silver(I) (6a):
A mixture of imidazolium salt 5a (95 mg, 0.20 mmol), CH2Cl2 (15 mL), and silver(I) oxide (46 mg, 0.20 mmol) was stirred at room temperature in the dark for 1 d. The suspension was filtered over Celite and the filtrate was concentrated in vacuum. The residue was dissolved in CH2Cl2 and the product precipitated with n-hexane. Yield: 72 mg (0.12 mmol, 61%); brown gum; 1 H NMR (300 MHz, CDCl3) !=3.55 (s, 6H), 3.9-4.3 (m, 9H), 7.2-7.5 (m, 5H); 13 (38) .
Iodido-(1,3-diethyl-4-ferrocenyl-5-phenylimidazol-2-ylidene)silver(I) (6b):
Analogously to 6a, compound 6b (90 mg, 0.15 mmol, 60%) was obtained from 5b (130 mg, 0.25 mmol), CH2Cl2 (15 mL), and silver(I) oxide (65 mg, 0.28 mmol) as a brown gum; 1 
Chlorido-(1,3-dimethyl-4-ferrocenyl-5-phenylimidazol-2ylidene)gold(I) (7a):
Complex 6a (70 mg, 0.12 mmol) was dissolved in CH2Cl2 (15 mL) and treated with chloro(dimethylsulfide)gold(I) (49 mg, 0.16 mmol). The reaction mixture was stirred at room temperature for 18 h. The suspension was filtered, the filtrate was concentrated in vacuum and the residue recrystallised from CH2Cl2/n-hexane. Yield: 60 mg (0.10 mmol, 86%); amber solid of m.p. 120 °C; 1 
Chlorido-(1,3-diethyl-4-ferrocenyl-5-phenylimidazol-2-ylidene)gold(I) (7b):
Analogously to 7a complex 7b (60 mg, 0.097 mmol, 81%) was obtained from 6b (75 mg, 0.12 mmol), CH2Cl2 (15 mL), and chloro(dimethylsulfide)gold(I) ( 
Triphenylphosphino-(1,3-diethyl-4-ferrocenyl-5-phenylimidazol-2ylidene)gold(I) tetrafluoroborate (8):
Complex 7b (45 mg, 0.073 mmol) was dissolved in acetone (10 mL) and treated with NaBF4 (15 mg, 0.136 mmol) and PPh3 (25 mg, 0.095 mmol). The reaction mixture was stirred at room temperature for 1 h. The suspension was filtered, the filtrate was concentrated in vacuum and the residue recrystallised from CH2Cl2/nhexane. Yield: 50 mg (0.054 mmol, 74%); amber solid of m.p. 183 °C (dec.); 1 H NMR (500 MHz, CDCl3) !=1. 33 
1,3-Diethyl-4-ferrocenyl-5-phenylimidazolium tetrafluoroborate (9):
A mixture of 5b (67 mg, 0.13 mmol), acetone (30 mL), and NaBF4 (22 mg, 0.20 mmol) was stirred at room temperature for 24 h. The mixture was filtered over MgSO4, the filtrate was concentrated in vacuum and the residue was dried. Yield: 60 mg (0.13 mmol, 100%); yellow gum; 1 
Bis-[1,3-diethyl-4-ferrocenyl-5-phenylimidazol-2-ylidene]gold(I) tetrafluoroborate (10):
Imidazolium salt 9 (60 mg, 0.13 mmol) was dissolved in CH2Cl2/methanol (1:1, 30 mL) and treated with Ag2O (34 mg, 0.14 mmol). The resulting mixture was stirred in the dark at room temperature for 5 h. Chloro(dimethylsulfide)gold(I) (23 mg, 0.075 mmol) was added and stirring was continued for a further 20 h. The suspension was filtered, the filtrate was concentrated in vacuum, and the residue was redissolved in CH2Cl2, and filtered over MgSO4/celite. The filtrate was concentrated and the remainder was dried in vacuum. Yield: 50 mg (0.05 mmol, 64%); amber solid of m.p. 183 °C (dec.); 1 Biological Studies. Enzyme: PARP-1 activity was determined using Trevigen's HT universal colorimetric PARP assay according to the manufacturer's instructions. It measures the incorporation of biotinylated poly(ADP-ribose) in histone proteins in a 96-microtiter strip well format. Recombinant human PARP-1 (high specific activity, purified from E. coli containing recombinant plasmid harboring the human PARP gene) was used as the enzyme source and incubated with different concentrations of complexes 8 and 10 for 1 h at room temperature prior to its addition to the histone proteins in the 96-well plates. The final reaction mixture (50 µL) was treated with TACS-Sapphire, a horseradish peroxidase colorimetric substrate, and incubated in the dark for 30 min. The absorbance was measured at 630 nm. The experiment was performed twice in duplicate and EC50 values are presented as means ± S.D..
The inhibition of thioredoxin reductase (TrxR) by 8 and 10 was assessed using a microplate reader based assay with minor modifications. [4, 38, 61] Rat liver TrxR (Sigma-Aldrich) was diluted with water to a concentration of 2.0 U/mL. To 25 µL aliquots of the enzyme solution 25 µL of potassium phosphate buffer pH 7.0 containing the complexes 8 and 10 in graded concentrations or vehicle (DMF) were added. The resulting solutions (final concentration of DMF: 0.5% v/v) were incubated for 75 min at 37 °C in a 96-well plate. To each well, 225 µL of the reaction mixture (1000 µL reaction mixture: 500 µL potassium phosphate buffer pH 7.0, 80 µL 100 mM EDTA solution pH 7.5, 20 µL BSA solution 0.05%, 100 µL of 20mM NADPH solution, and 300 µL of distilled water) were added and the reaction was started by adding 25 µL of a 20 mM DTNB solution. The formation of 5-TNB was monitored with a Perkin-Elmer Victor X4 microplate reader at 405 nm in 10 s intervals for 6 min. The increase in 5-TNB concentrations over time followed a linear trend (r 2 % 0.99), and the enzymatic activities were calculated as the slopes (increase in absorbance per second) thereof. The noninterference of the test compounds with the assay components was confirmed by negative control experiments with enzyme-free solution. The EC50 values are the complex concentrations decreasing the enzymatic activity to 50%, given as means ± S.D. of two or three experiments in duplicate.
Tube Formation Assay:
The interference of 8 and 10 with the formation of vascular-like tubular networks by HUVEC was investigated in vitro. HUVEC (25 !L of 8!10 5 cells/mL) were seeded on matrigel (BD Biosciences) in black 96-well plates and treated with 8 or 10 (dilution of 10 mM stock solutions in DMF ranging from 50 nM to 10 µM in H2O) to identify antiangiogenic activity. Solvent controls (DMF) were treated identically. Effects were documented by light microscopy after 24 h of incubation (Axiovert 35, 5! objective lens, AxioCam color, Zeiss). [9, 53, 62] Chorioallantoic Membrane (CAM) Assay: Fertilized, specific pathogenfree (SPF) chicken eggs (VALO BioMedia) were bred in an incubator at 37 °C and 60% relative humidity. On day 6 windows (Ø 1.5-2 cm) were cut into the shell at the more rounded pole of the egg. The holes were sealed with tape, and incubation was continued overnight. Rings of silicon foil (Ø 5 mm) were placed on the CAM with its developing blood vessels, and complexes 8 or 10 (2.5 nmol), or DMF as control (all in a volume of 10 !L H2O) were topically applied within the rings. The effects on the developing vasculature were documented after incubation for 6 h and 24 h using a light microscope (60! magnification, Traveler). The fractal analyses to quantify a decrease in areas covered by blood vessels after 6 h of incubation with the test compounds was carried out as described before using ImageJ 1.48f (FracLac_2015Jul plugin) and the Fractal Analysis System 3.4.7 software. [9] Mouse Xenograft Model: The animal studies had been approved by the committee on animal care (Government of Rhineland-Palatinate). The mice (Balb/c) were kept under a 12 h light-dark cycle in a controlled conventional colony room. They had free access to sterilized water and standard rodent diet ad libitum. They were sacrificed by cervical dislocation corresponding to the guidelines of the committee on animal care. To analyze the in vivo antitumor activity and tolerance of gold complex 10, a Balb/c mouse xenograft model of highly metastatic B16-F10 mouse melanoma cells was used. A suspension of 2 ! 10 5 cells in 200 mL PBS was administered to the flanks of each mouse to generate subcutaneous xenograft tumors. Freshly prepared 9 mM stock solutions of complex 10 in DMSO were diluted 1:9 with PBS and injected i.p. twice on two consecutive days (days 1, 2, and 7, 8) in the mice (n=3) at 7.5 mg ! (kg body weight) -1 . Control mice (n=3) were treated with respective amounts of DMSO (in PBS). The size of the tumors was recorded daily, beginning on the day of the first injection. Tumor volumes were calculated by the formula a 2 ! b ! 0.5, with a being the short and b the long dimension. The weight of the mice was measured at the beginning (day 1) and at the end of the experiment (day 12) and was used as an indication of drug tolerance.
Further tests: For details on the studies of growth inhibition, cellular accumulation, partition coefficients, interference with F-actin and mitochondrial membrane potential, cell cycle, wound healing, and ROS generation refer to the Supporting information.
